Custo-efetividade de cardiodesfibriladores implantáveis no Brasil nos setores público e privado

Ribeiro, Rodrigo Antonini; Stella, Steffan Frosi; Zimerman, Leandro Ioschpe; Pimentel, Maurício; Rohde, Luís Eduardo Paim; Polanczyk, Carísi Anne

doi:10.1590/s0066-782x2010005000134

Cited by 21 publications

(8 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Advanced treatments such as implantable cardioverter defibrillators or cardiac synchronisation therapy are potentially cost-effective in some places (eg, Brazil), but are expensive. 98 The use of thrombolytic therapy to treat ischaemic stroke requires timely access to CT; and, if built only to diagnose stroke, these facilities are as yet unaffordable. As costs drop, and skilled providers are trained, additional capacity to diagnose and manage more complex disease should become available in specialised facilities (panel 2).…”

Section: Pathways To Addressing Cvrds In Lmicsmentioning

confidence: 99%

Cardiovascular, respiratory, and related disorders: key messages from Disease Control Priorities, 3rd edition

et al. 2018

View full text Add to dashboard Cite

Cardiovascular, respiratory, and related disorders (CVRDs) are the leading causes of adult death worldwide, and substantial inequalities in care of patients with CVRDs exist between countries of high income and countries of low and middle income. Based on current trends, the UN Sustainable Development Goal to reduce premature mortality due to CVRDs by a third by 2030 will be challenging for many countries of low and middle income. We did systematic literature reviews of effectiveness and cost-effectiveness to identify priority interventions. We summarise the key findings and present a costed essential package of interventions to reduce risk of and manage CVRDs. On a population level, we recommend tobacco taxation, bans on trans fats, and compulsory reduction of salt in manufactured food products. We suggest primary health services be strengthened through the establishment of locally endorsed guidelines and ensured availability of essential medications. The policy interventions and health service delivery package we suggest could serve as the cornerstone for the management of CVRDs, and afford substantial financial risk protection for vulnerable households. We estimate that full implementation of the essential package would cost an additional US$21 per person in the average low-income country and $24 in the average lower-middle-income country. The essential package we describe could be a starting place for low-income and middle-income countries developing universal health coverage packages. Interventions could be rolled out as disease burden demands and budgets allow. Our outlined interventions provide a pathway for countries attempting to convert the UN Sustainable Development Goal commitments into tangible action.

show abstract

Section: Pathways To Addressing Cvrds In Lmicsmentioning

confidence: 99%

Cardiovascular, respiratory, and related disorders: key messages from Disease Control Priorities, 3rd edition

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Ribeiro et al42 evaluated the cost-effectiveness of Implantable Cardioverter Defibrillators in congestive heart failure patients under two perspectives in Brazil: public and supplementary health systems. They conclude that the incremental cost-effectiveness ratio of Implantable Cardioverter Defibrillators is elevated in the general heart failure population, in either the public or private perspective.…”

Section: Introductionmentioning

confidence: 99%

A survey of recently published cardiovascular, hematological and pneumological original articles in the Brazilian scientific press

Patel¹,

Caramelli²,

Gomes³

2011

Clinics

View full text Add to dashboard Cite

Recent original scientific contributions published in selected Brazilian periodicals and classifiable under cardiovascular and pulmonary subject categories cover a wide range of sub specialties, both clinical and exprimental. Because they appear in journals with only recently enhanced visibility, we have decided to highlight a number of specific items appeared in four Brazilian journals, because we understand that this is an important subsidy to keep our readership adequately informed. These papers cover extensive sub-areas in both fields.

show abstract

“…According to the guidelines for the economic evaluation proposed by the Ministry of Health (MS), the hospitalization costs obtained from the AIH values have been used in almost all studies conducted in Brazil, although the AIH is criticized for representing the values reimbursed and not necessarily the actual costs 6 . In this context, we can observe the use of the average value of the AIH, which was obtained from the analysis of the SIH/SUS, in studies with the most varied objectives, such as: disease cost assessment 2 , 8 , analysis of vaccine efficacy 9 , 10 , efficiency of new diagnostic technologies 4 , efficiency of programs 11 , and efficiency of new therapeutic technologies 12 , among others.…”

Section: Discussionmentioning

confidence: 99%

Deficiência de glicose-6-fosfato desidrogenase e uso de primaquina: estimativa de custos de profissionais por macrocusteio e microcusteio

et al. 2017

View full text Add to dashboard Cite

The aim of this study has been to study whether the top-down method, based on the average value identified in the Brazilian Hospitalization System (SIH/SUS), is a good estimator of the cost of health professionals per patient, using the bottom-up method for comparison. The study has been developed from the context of hospital care offered to the patient carrier of glucose-6-phosphate dehydrogenase (G6PD) deficiency with severe adverse effect because of the use of primaquine, in the Brazilian Amazon. The top-down method based on the spending with SIH/SUS professional services, as a proxy for this cost, corresponded to R$60.71, and the bottom-up, based on the salaries of the physician (R$30.43), nurse (R$16.33), and nursing technician (R$5.93), estimated a total cost of R$52.68. The difference was only R$8.03, which shows that the amounts paid by the Hospital Inpatient Authorization (AIH) are estimates close to those obtained by the bottom-up technique for the professionals directly involved in the care.

show abstract

Custo-efetividade de cardiodesfibriladores implantáveis no Brasil nos setores público e privado

Cited by 21 publications

References 34 publications

Cardiovascular, respiratory, and related disorders: key messages from Disease Control Priorities, 3rd edition

Cardiovascular, respiratory, and related disorders: key messages from Disease Control Priorities, 3rd edition

A survey of recently published cardiovascular, hematological and pneumological original articles in the Brazilian scientific press

Deficiência de glicose-6-fosfato desidrogenase e uso de primaquina: estimativa de custos de profissionais por macrocusteio e microcusteio

Contact Info

Product

Resources

About